PRIME® Continuing Medical EducationNavigating Endocrine Resistance: Latest Strategies in HR+/HER2- Breast Cancer CareWhile endocrine therapies are widely employed for treating HR+/HER2- breast cancer, many patients with advanced or metastatic disease eventually develop resistance. As the treatment landscape continues to evolve, it is important to stay up to date on key advancements in managing endocrine resistance in this setting.
